Ten-year outcomes of anti-vascular endothelial growth factor treatment for neovascular age-related macular disease: A single-centre French study
- 1 July 2020
- journal article
- research article
- Published by Wiley in Clinical & Experimental Ophthalmology
- Vol. 48 (5), 636-643
- https://doi.org/10.1111/ceo.13742
Abstract
Importance Long-term data of intravitreal injections of vascular endothelial growth factor (VEGF) inhibitors are lacking. Background This study aims to assess visual and anatomic outcomes of eyes with neovascular age-related macular degeneration (nAMD) after 10 years of anti-VEGF therapy. Design Retrospective analysis of data from a prospectively designed database. Participants One hundred and sixteen eyes with nAMD (94 participants) that started anti-VEGF therapy at least 10 years earlier. Methods Eyes were tracked by the Fight Retinal Blindness! registry. Main Outcome Measures Mean change in visual acuity at 10 years vs baseline. Visual acuity was assessed by the number of letters read on a logarithm of the minimum angle of resolution chart. Results Eyes received a median of 27.5 injections over 10 years. Mean visual acuity was 57.5 letters (SD 17.5) at baseline. It increased slightly at 1 year, then dropped steadily by 18 letters (95% CI: 13.7; 22.3) at 10 years. Overall, 10% of eyes gained >= 10 letters, 64% lost >= 10 letters and 23% remained stable (+/- 5 letters from baseline). Geographic atrophy and subretinal fibrosis were found in 93% and 71%, respectively, after 10 years, both mostly affecting the centre of the fovea. Pre-treated eyes (47.5%) had significantly worse visual acuity than treatment-naive eyes at baseline and during follow-up and were significantly more likely to have atrophy and fibrosis. Conclusions and Relevance Despite short-term stabilization, long-term visual outcomes of nAMD eyes under anti-VEGF therapy may be poor. Development of atrophy and fibrosis, resulting from the natural progression of the disease, may partly explain this evolution.This publication has 27 references indexed in Scilit:
- Macular Atrophy Progression and 7-Year Vision Outcomes in Subjects From the ANCHOR, MARINA, and HORIZON Studies: the SEVEN-UP Study∗American Journal of Ophthalmology, 2015
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studiesInternational Journal of Surgery, 2014
- Consequences of long‐term discontinuation of vascular endothelial growth factor inhibitor therapy in the patients with neovascular age‐related macular degenerationActa Ophthalmologica, 2014
- Photodynamic Therapy in Subfoveal and Juxtafoveal Myopic Choroidal Neovascularization: A 10-year Retrospective AnalysisOphthalmologica, 2014
- EFFICIENT CAPTURE OF HIGH-QUALITY DATA ON OUTCOMES OF TREATMENT FOR MACULAR DISEASESRetina, 2014
- Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments TrialsOphthalmology, 2013
- Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZONOphthalmology, 2013
- Results of One-Year's Treatment with Ranibizumab for Exudative Age-related Macular Degeneration in a Clinical SettingAmerican Journal of Ophthalmology, 2009
- The Natural History and Prognosis of Neovascular Age-Related Macular Degeneration: A Systematic Review of the Literature and Meta-analysisOphthalmology, 2008
- Resolution of subretinal haemorrhage and fluid after intravitreal bevacizumab in aggressive peripapillary subretinal neovascularizationActa Ophthalmologica Scandinavica, 2006